EUVIMEDEUVIMED entdecken
Leitlinie

Preference for anti-phospholipase A2 receptor antibody assay in patients with suspected membranous nephropathy: a survey study on medical practice after publication of Japanese Guidelines for Nephrotic Syndrome 2020

Sho Sasaki, Sayaka Shimizu, Izaya Nakaya, Yoshitaka Miyaoka, Masahiro Koizumi, Hiroki Nishiwaki, Tadashi Sofue, Takuji Ishimoto, Noriaki Kurita, Takehiko Wada

Clinical and Experimental Nephrology · 2024

DOI: 10.1007/s10157-024-02462-1 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Sho Sasaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Education for Clinical Research, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Practice Patterns, Physicians', Practice Guidelines as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Japan Intractable Diseases Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: International practice guidelines advocate for the use of anti-phospholipase A2 receptor (PLA2R) antibody testing to diagnose primary membranous nephropathy (pMN). This study aimed to clarify the current status of anti-PLA2R antibody testing in the diagnosis of pMN in Japan and to scrutinize the factors associated with the implementation of this antibody test. METHODS: Utilizing a web-based questionnaire for nephrologists, responses were collected from 306 facilities and 427 nephrologists between November 2021 and December 2021. Preference for anti-PLA2R antibody testing was also investigated. Factors related to the experience of quantifying anti-PLA2R antibodies were estimated by generalized estimating equations using a robust analysis of variance with clusters of facilities of affiliation. RESULTS: Of the 427 respondents, 140 (32.8%) had previous measurement experience at their current workplace and 165 (38.6%) had previous measurement experience overall. In pMN-suspected cases without contraindications to renal biopsy, 147 (34.4%) of the respondents opted to request anti-PLA2R antibody testing. The respondents' experience with anti-PLA2R antibody quantification at their current place of work was generally higher in university hospitals and increased with the annual number of kidney biopsies and the number of years since graduation. CONCLUSION: The results of this study suggest that a significant proportion of nephrologists in Japan have no experience in performing anti-PLA2R antibody assays, and that the assays may be hampered by the limited capabilities of the current workplace and the financial burden on facilities and patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousReceptors, Phospholipase A2Practice Patterns, Physicians'Practice Guidelines as TopicHumansJapanAutoantibodiesSurveys and QuestionnairesNephrotic SyndromeMaleEast Asian People

Stichwörter der Autor:innen

AdultAnti-phospholipase A2 receptor antibodiesGuideline adherenceNephrosisPrimary membranous nephropathy

Substanzen

Receptors, Phospholipase A2AutoantibodiesPLA2R1 protein, human

Autor:innen und Institutionen

  • Section of Education for Clinical Research, Kyoto University Hospital, Kyoto, Japan.
  • Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan.
  • Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ssayaka.tkshm@gmail.com.
  • Patient Driven Academic League (PeDAL), Tokyo, Japan. ssayaka.tkshm@gmail.com.
  • Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan. ssayaka.tkshm@gmail.com.
  • Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Iwate, Japan.

Förderung

  • Japan Intractable Diseases Research Foundation

Zitieren

APA

Sasaki, S., Shimizu, S., Nakaya, I., Miyaoka, Y., Koizumi, M., Nishiwaki, H., Sofue, T., Ishimoto, T., Kurita, N., & Wada, T. (2024). Preference for anti-phospholipase A2 receptor antibody assay in patients with suspected membranous nephropathy: a survey study on medical practice after publication of Japanese Guidelines for Nephrotic Syndrome 2020. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02462-1

Vancouver

Sasaki S, Shimizu S, Nakaya I, Miyaoka Y, Koizumi M, Nishiwaki H, et al. Preference for anti-phospholipase A2 receptor antibody assay in patients with suspected membranous nephropathy: a survey study on medical practice after publication of Japanese Guidelines for Nephrotic Syndrome 2020. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02462-1

BibTeX
@article{Sasaki2024,
  author = {Sasaki, Sho and Shimizu, Sayaka and Nakaya, Izaya and Miyaoka, Yoshitaka and Koizumi, Masahiro and Nishiwaki, Hiroki and Sofue, Tadashi and Ishimoto, Takuji and Kurita, Noriaki and Wada, Takehiko},
  title = {Preference for anti-phospholipase A2 receptor antibody assay in patients with suspected membranous nephropathy: a survey study on medical practice after publication of Japanese Guidelines for Nephrotic Syndrome 2020},
  journal = {Clinical and Experimental Nephrology},
  year = {2024},
  doi = {10.1007/s10157-024-02462-1}
}
Kostenlos starten →